Keep the details together.
- Product scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
- Route and preparation
- Specified subcutaneous formulation.
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limits of the reference
- Not for weight management.
- Safety context
- Active malignancy is a contraindication.
A note on reading the evidence.
Read the entry rules before deciding whom a result describes. A headline may name a broad audience, while the report gives a more specific account of who could take part. If those descriptions differ, write down the difference in ordinary language. Then ask which part of the claim depends on extending the result beyond the study group. This is a way to prepare a focused discussion about relevance. It does not require assuming that an excluded person would respond differently, or that everyone who met the entry rules would respond alike.
Questions to open a conversation.
- Who could enter the study under the stated participation rules?
- Is the audience named in the claim broader than that group?
- What evidence supports extending the conclusion beyond the people included?
Source reading.
- EGRIFTA WRNLM · Checked
- Falutz trialPubMed · Checked